Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Discover OXSQH's 7.75% yield and investment-grade quality. With well-covered payments and a 20-year dividend history, it's a ...

Eldorado's stock has performed exceptionally well this year, rising more than 50% on the back of gold's momentum and Skouries ...

Super investors like Buffett and Michael Bury piled heavily into UnitedHealthcare in Q2, signalling confidence that the ...

Morgan Stanley 4.250% Depositary Shares Non-Cumulative Preferred Stock, Series O offers a compelling risk-reward profile in ...

Crescent Capital BDC posted strong Q2 income and dividend coverage, yet trades at a steep 21% NAV discount despite solid ...

Afya's Q2 2025 results were solid, but the stock faces headwinds from market saturation and regulatory changes in Brazil's ...

T-Mobile debuts investment-grade baby bonds (TMUSZ, TMUSL, TMUSI) maturing 2069–2070. Explore yields up to 6.22% and strong ...

BP delivered strong Q2 results, beating earnings and revenue estimates due to strong profitability in its core business.

The real assets portfolio was the primary detractor due to negative returns for energy stocks and U.S. real estate investment ...

Novo Nordisk (NVO) stock in focus as the company wins FDA accelerated nod for weight loss therapy Wegovy against the liver ...

Healthcare Opportunities Fund offers a compelling way to play the healthcare sector. Read here for an analysis of THQ CEF.